UCSF home page UCSF home page About UCSF Search UCSF UCSF Medical Center
UCSF navigation bar

The Ins and Outs of Genitourinary Cancer


Spring 2014

Tuesday evenings – June 17 – July 22
7-8:30pm, Nursing School Building, Room N-225, 513 Parnassus Avenue, San Francisco
Course Number: MLL14021

As the title of this course illustrates, clinical practice informs basic science research, and that research in turn informs clinical practice. The field of oncology is an excellent example of this – discoveries in molecular biology and genetics have revolutionized clinical care for patients with cancer. New genomic technologies are allowing us to understand molecular changes that underlie cancer development, with the promise of more specific diagnoses and individualized treatment options. In this course, genitourinary cancers will be discussed with an emphasis on how research and advances in technologies are impacting clinical care of cancer in the urinary tract and male genital tract.

Course Chair
Charles J. Ryan, MD

Professor of Clinical Medicine and Urology
Program Leader, Genitourinary Medical Oncology, UCSF Helen Diller Family Comprehensive Cancer Center

Download the SPRING 2014 registration form here

Register online here

(You will be prompted to login to your account. If you have registered for an Osher Mini Medical course in the past, you are already in our system and your login is your email address.  If this is your first course, please create a new account.)


June 17 – Charles J. Ryan, MD  | BIO | Handout
Professor of Clinical Medicine and Urology
Program Leader, Genitourinary Medical Oncology, UCSF Helen Diller Family Comprehensive Cancer Center
Advanced Prostate Cancer
Overview: Prostate cancer kills approximately 30,000 men in the US every year. For many, the disease is highly treatable and can be controlled with medical therapy for many years. An understanding of the factors that drive prostate cancer to become potentially lethal has led to a variety of new treatments that go far beyond standard chemotherapy approaches to cancer. Patients with advanced prostate cancer are currently treated with combinations and sequences of immunotherapies, hormonal approaches and chemotherapy. The session will cover the clinical and biological factors that drive treatment choice and sequence by physicians, and will highlight how prostate cancer therapies are emblematic of the progress that is being made against cancer in general. Further, we will address the challenges faced by patients and doctors and the research being done to address them.

June 24 – Terry Friedlander, MD | BIO
Assistant Clinical Professor, Hematology/Oncology
Bladder Cancer
OverviewBladder cancer: This is the 5th most common cancer and is much more common in smokers. The talk will review the basic biology and pathophysiology of bladder cancer, focusing on methods used to detect bladder cancer, treatment of early-stage disease with therapies administered into the bladder, the role of surgery or radiation therapy in the treatment localized disease, the role of chemotherapy for metastatic disease, and new directions in the field, particularly the role of immunotherapy in bladder cancer.

July 1 – Terry Friedlander, MD | BIO
Assistant Clinical Professor, Hematology/Oncology
Testicular Cancer
Overview: This is the most common cancer in young men and is a model of a curable cancer. This talk will review the basic biology of testicular cancer and discuss the management of the disease, focusing on the clinical presentation, management of early stage disease, role of multimodality treatment, survivorship and the long term effects of chemotherapy and radiation, and discuss questions facing the field today, including the role of autologous bone marrow transplantation for advanced disease.

July 8 – Michael W. Rabow, MD | BIO | Handout
Director, Symptom Management Service, Helen Diller Family Comprehensive Cancer Center
Director, Symptom Management & Palliative Care Consultation Service, UCSF/Mount Zion Hospital
Professor of Clinical Medicine
Palliative Medicine/ Symptom Management
Overview: Palliative care provides an extra layer of support for people facing serious illnesses, including genitourinary cancers. Unfortunately, many patients, loved ones, and even clinicians do not accurately understand what palliative care is and when it should be offered. This presentation will explain what palliative care is, describe the symptoms commonly caused by genitourinary cancers (as well as by their treatments), and review the evidence demonstrating the benefits of palliative care for genitourinary cancers. Finally, this talk will describe the current availability of palliative care specialists in California and the US. Both local UCSF experience and national data will be presented.

July 15 – Won Kim, MD | BIO
Clinical Fellow
Kidney Cancer
Overview: In the United States, there are over 60,000 new diagnoses and nearly 14,000 deaths from kidney cancer each year. This talk will review the epidemiology of kidney cancer (including established risk factors), the biology and pathophysiology of kidney cancer, treatment options for localized disease, and the role of systemic therapy in the treatment of advanced, metastatic disease. The talk will also focus on current and future role of immunotherapy in kidney cancer.

July 22 – Matthew R. Cooperberg, MD, MPH | BIO | Handout
Associate Professor of Urology; Epidemiology & Biostatistics Helen Diller Family Chair in Urology
Early Prostate Cancer


Comments are closed.